AXON market cap, 1.3 Billion. Previously failed dr
Post# of 72446
Posted On: 07/18/2016 11:39:20 AM
AXON market cap, 1.3 Billion. Previously failed drug in clinical trial.
AVXL market cap, 264.65 million. Alzheimer's drug in very small Phase 1 trial. NOTE: I still own some AVXL though I sold some in the pumper-driven run-up. They have a small grant from Michael J. Fox Foundation for animals studies of their Alz drug, in Parkinson's. Talking about setting up clinical trial to for epilepsy.
CTSO market cap 124 million. Blood filter to be used in toxic shock syndrome. Has CE mark in Europe, not FDA approved here.
NNVC market cap, 93.45 Million. No clinical trial, in the lab for years longer than CTIX with nothing to show for it (except a new lab the shareholders paid for).
ARTH market cap around 80 million (was over 100 million when pumpers ran it up, then tanked it last week). New, very promising surgical glue, in clinical trials.
AVXL market cap, 264.65 million. Alzheimer's drug in very small Phase 1 trial. NOTE: I still own some AVXL though I sold some in the pumper-driven run-up. They have a small grant from Michael J. Fox Foundation for animals studies of their Alz drug, in Parkinson's. Talking about setting up clinical trial to for epilepsy.
CTSO market cap 124 million. Blood filter to be used in toxic shock syndrome. Has CE mark in Europe, not FDA approved here.
NNVC market cap, 93.45 Million. No clinical trial, in the lab for years longer than CTIX with nothing to show for it (except a new lab the shareholders paid for).
ARTH market cap around 80 million (was over 100 million when pumpers ran it up, then tanked it last week). New, very promising surgical glue, in clinical trials.
(0)
(0)